Why the study?
New evidence on HCM diagnosis, management, and prognosis has accumulated since previous guidelines, expanding the role of multi-modality imaging in HCM.
This clinical consensus statement by the EACVI provides updated, state-of-the-art guidance on the use of multimodality imaging for the diagnosis, symptom assessment, prognostic stratification, and screening of hypertrophic cardiomyopathy.
Clinicians should implement updated multi-modality imaging pathways for HCM; extends 2023 ESC and 2015 EACVI guidance.
After the 2014, European Society of Cardiology (ESC) guidelines on hypertrophic cardiomyopathy (HCM) were published, the European Association of Cardiovascular Imaging (EACVI) of the ESC developed the 2015 EACVI consensus paper on multi-modality imaging (MMI) in HCM, providing in-depth knowledge on the role of imaging in this disease. Since then, new evidence on HCM diagnosis, management and patient prognosis has accumulated, and the role of MMI has further expanded. Now that the 2023 ESC guidelines on cardiomyopathies have been published, a new EACVI document on MMI in HCM is needed, providing state-of-the-art, in-depth knowledge of imaging in HCM. The scope of this document is to focus on the role of the different imaging techniques in HCM in a logical, didactic and comprehensive way using a multi-modality approach. We provide our vision for future directions on MMI in HCM.
No takes yet. Share an insight, caveat, or question.
Cardim et al. (2025) conducted a review in Hypertrophic cardiomyopathy. Multi-modality cardiac imaging was evaluated. Multi-modality cardiac imaging, including echocardiography and cardiac magnetic resonance, is essential for the contemporary diagnosis, symptom evaluation, and prognostic risk stratification of hypertrophic cardiomyopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: